Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.42 |
| ▸ | CTSS | P25774 | 7/20 | 0.41 |
| ▸ | CTSK | P43235 | 7/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20415708 | 0.94 | TAS1R3 (0.52) | KLK5TAS1R3TAS1R1CTSSCTSK | |
| SCHEMBL18262693 | 0.94 | TAS1R3 (0.52) | KLK5TAS1R3TAS1R1CTSSCTSK | |
| SCHEMBL24503057 | 0.92 | KLK5 (0.46) | KLK5NLRP3CTSSCTSKCTSB | |
| SCHEMBL1744721 | 0.86 | KLK5 (0.50) | KLK5CTSSCTSKCTSBACE | |
| SCHEMBL1744724 | 0.86 | KLK5 (0.50) | KLK5CTSSCTSKCTSBACE | |
| SCHEMBL20415861 | 0.84 | REN (0.46) | TAS1R3TAS1R1CTSSCTSKCTSB | |
| SCHEMBL18262463 | 0.84 | ACE (0.52) | CTSSCTSKCTSBACE | |
| SCHEMBL18262461 | 0.84 | ACE (0.52) | CTSSCTSKCTSBACE | |
| SCHEMBL24502279 | 0.81 | KLK5 (0.48) | KLK5NLRP3CTSSCTSKCTSB | |
| SCHEMBL22604574 | 0.80 | KLK5 (0.50) | KLK5NLRP3CTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858314-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2020-12-08 | — | — | US | disclosed |
| US-10858314-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2020-12-08 | — | — | US | disclosed |
| EP-3303284-B1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN SEIYAKU KK (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858314-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, SAAL1, FPR2 | KLK5 3956/4885TAS1R3 1393/4885TAS1R1 602/4885 |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, SAAL1 | KLK5 3708/4885TAS1R3 1498/4885TAS1R1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.